Q3 2018 EPS Estimates for Proteostasis Therapeutics Inc Reduced by Analyst (PTI)

Proteostasis Therapeutics Inc (NASDAQ:PTI) – Leerink Swann lowered their Q3 2018 earnings per share estimates for Proteostasis Therapeutics in a research note issued on Thursday, August 9th. Leerink Swann analyst J. Schwartz now expects that the company will earn ($0.45) per share for the quarter, down from their previous estimate of ($0.33). Leerink Swann also issued estimates for Proteostasis Therapeutics’ Q4 2018 earnings at ($0.47) EPS, FY2018 earnings at ($1.68) EPS, FY2019 earnings at ($1.81) EPS and FY2020 earnings at ($1.76) EPS.

Proteostasis Therapeutics (NASDAQ:PTI) last announced its quarterly earnings results on Wednesday, August 8th. The company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.04). Proteostasis Therapeutics had a negative return on equity of 96.42% and a negative net margin of 1,087.27%.

Other research analysts also recently issued reports about the company. Zacks Investment Research downgraded Proteostasis Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 1st. ValuEngine upgraded Proteostasis Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 7th. Finally, Royal Bank of Canada downgraded Proteostasis Therapeutics from an “outperform” rating to a “sector perform” rating and cut their price objective for the stock from $11.00 to $5.00 in a research report on Thursday, June 7th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $12.25.

Shares of NASDAQ:PTI opened at $2.39 on Monday. The company has a market cap of $89.91 million, a PE ratio of -1.02 and a beta of 3.89. Proteostasis Therapeutics has a 12 month low of $1.41 and a 12 month high of $8.61.

Institutional investors have recently modified their holdings of the stock. Schwab Charles Investment Management Inc. raised its position in shares of Proteostasis Therapeutics by 156.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 46,900 shares of the company’s stock worth $131,000 after purchasing an additional 28,600 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of Proteostasis Therapeutics during the 2nd quarter worth approximately $141,000. Trexquant Investment LP acquired a new position in shares of Proteostasis Therapeutics during the 1st quarter worth approximately $149,000. Element Capital Management LLC acquired a new position in Proteostasis Therapeutics in the 1st quarter valued at $158,000. Finally, Bayesian Capital Management LP acquired a new position in Proteostasis Therapeutics in the 1st quarter valued at $159,000. Hedge funds and other institutional investors own 67.39% of the company’s stock.

Proteostasis Therapeutics Company Profile

Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis and other diseases caused by an imbalance in the proteostasis network. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class, which is in Phase II study.

Recommended Story: Investing in Growth Stocks

Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply